Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

Capacity impact Switching from comparator treatment options to durvalumab with tremelimumab may have capacity implications. Transitioning from atezolizumab with bevacizumab is expected to save 1 ...

Guidance by programme NICE guidelines (1) Review the evidence across broad health and social care topics. Technology appraisal guidance (11) Reviews the clinical and cost-effectiveness of new ...

Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults. Last reviewed: 19 August 2025 Next review: ...

3 Committee discussion The evaluation committee considered evidence submitted by AstraZeneca, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See ...

Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults ...

Durvalumab (Imfinzi) with tremelimumab (Imjudo) is available on the NHS. It is a possible treatment for advanced or unresectable (cannot be surgically removed) hepatocellular carcinoma (liver cancer) ...

Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab ...